New insider activity at Alzamend Neuro ( (ALZN) ) has taken place on September 30, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Milton C III Ault has recently sold 79,628 shares of Alzamend Neuro stock, amounting to a total transaction value of $183,628.
Recent Updates on ALZN stock
Alzamend Neuro recently issued 300,000 shares of common stock following the conversion of 696 shares of Series B Convertible Preferred Stock, increasing its total outstanding common stock to 3,439,861 shares. This move is seen as a strategic financial maneuver to enhance the company’s liquidity or capital structure. The most recent analyst rating for Alzamend Neuro stock is a Hold with a price target of $6.90, reflecting cautious sentiment amidst these changes. The technical sentiment signal is a Sell, and the current market cap stands at $7.47 million.
More about Alzamend Neuro
YTD Price Performance: -77.39%
Average Trading Volume: 151,839
Technical Sentiment Signal: Sell
Current Market Cap: $7.41M